A prevention blood panel rests on a base of standardized tests
A prevention blood panel starts with standardized, reproducible and widely validated tests: fasting venous glucose, HbA1c, lipids and blood pressure, creatinine with estimated glomerular filtration rate, TSH. These measurements describe a cardiometabolic risk and never constitute a measure of biological age. Their advantage lies in being actionable, because they change with diet and physical activity. Their cost remains accessible, a few tens of euros for the basic cardiometabolic base. An indicator with no associated course of action provides only decorative information.
The US Preventive Services Task Force recommendations frame screening for diabetes, hyperlipidemia and hypertension in asymptomatic adults, with regular updates. In France, the Haute Autorité de santé publishes cardiovascular prevention guidelines that converge on the same risk groups. The professional justifies each line of the prescription on these frameworks, rather than on the habit of a broad panel. That shared reference secures both the decision and the way results are explained.
Two drifts are commonly observed: systematic vitamin D and TSH testing in people with no warning sign, and requests for very broad panels with no clinical reason. Vitamin D testing keeps an interest with low sun exposure, a history of fracture, osteoporosis risk or long-term corticosteroid therapy. TSH is justified in the face of suggestive clinical signs, a family history, an abnormal heart rate or unexplained fatigue. Restricting these indications avoids false positives and cascade investigations. The same reserve applies to a global iron, liver or thyroid panel, useful in a precise context and diluted in a routine prescription.
HbA1c: the first marker to confirm before any conclusion
HbA1c is the reference marker for average glycemic balance over about three months. It separates prediabetes between 5.7% and 6.4% from diabetes from 6.5%, subject to confirmation when the result is isolated. A drop of 0.3 to 0.5 points over three months generally signals an improvement in balance, obtained through losing a few kilos and regular physical activity. The result is nonetheless read with a margin, because individual biological variation can reach one to two points with no change in health status. HbA1c therefore describes a trajectory rather than a single point.
A slightly elevated HbA1c never justifies a disease label before the context is checked. The measurement varies with hemoglobin, iron deficiency, kidney failure, pregnancy and certain treatments. Hemoglobinopathy produces a distorted value, and the laboratory usually flags it on the report. The professional looks for these artefactual situations before concluding, and documents them. Repeating a close test with no explanation adds nothing and feeds worry.
Fasting venous glucose usefully completes HbA1c when doubt remains about fasting glycemia. It remains the simplest reference for confirming diabetes in the face of unexplained hyperglycemia. A glucose level between 1.10 g/L and 1.26 g/L defines diabetes when a second measurement confirms it. This combination gains in precision. It does not needlessly burden the prescription.
| Marker | Reference value | Documented action threshold | Associated course of action |
|---|---|---|---|
| Fasting venous glucose | 0.70 to 1.10 g/L | 1.10 g/L prediabetes, 1.26 g/L diabetes | Confirmation then support and a new check |
| HbA1c | 4.0 to 5.6% | 5.7% prediabetes, 6.5% diabetes | Diet and activity, remeasurement at three months |
| LDL cholesterol | Target depends on risk | 1.30 g/L, 0.70 g/L, 0.55 g/L depending on risk | Lifestyle and diet first, then decision on treatment |
| HDL cholesterol | Above 0.40 g/L | Below 0.40 g/L in men | Assessment of the total cholesterol to HDL ratio |
| Triglycerides | Below 1.50 g/L | Above 1.50 g/L, then 2.00 g/L | Look for diabetes, hypothyroidism, excess alcohol |
| Blood pressure | Target below 130/80 mmHg | 140/90 mmHg in the office, 135/85 mmHg at home | Confirmation by home measurement or by a professional |
Quantified markers of the prevention panel in asymptomatic adults

Lipids are read against overall cardiovascular risk
Lipids are never read as absolute values, but against the estimated overall cardiovascular risk. LDL cholesterol targets tighten as risk increases: 1.30 g/L at moderate risk, 0.70 g/L at high risk, 0.55 g/L at very high risk. The practitioner uses a validated risk scale, which combines age, smoking, blood pressure, diabetes and total cholesterol. This approach corrects the most frequent error, insufficient treatment in a high-risk person.
Non-HDL cholesterol completes the reading in people with elevated triglycerides. It is calculated by subtracting HDL cholesterol from total cholesterol, and it enters the risk formula of the Haute Autorité de santé. An HDL cholesterol below 0.40 g/L in men constitutes a risk factor to document, as does a value below 0.50 g/L in women. Hypertriglyceridemia, hypothyroidism, poorly controlled diabetes and excess alcohol distort the lipid panel. The professional looks for these causes before concluding on familial dyslipidemia.
The course of action for dyslipidemia starts with lifestyle and diet, whose effect on LDL cholesterol commonly reaches 10 to 15%. Regular physical activity, reduced saturated fat and smoking cessation change the other risk factors. The decision on drug treatment rests on overall risk, age and the existence of organ damage. Documenting the risk level in the file conditions this entire sequence.
The announced biological age stays outside clinical decision
Commercial biological age measurements are offered from DNA methylation, telomere length or metabolite panels, with prices frequently above one hundred and fifty euros. Comparison work shows that these indicators do not agree with one another. Their individual reproducibility remains lower than that of classic clinical tests. No trial has demonstrated that such a result changes a decision, improves a prognosis or gains years of life.
The associations between these indicators and mortality are observed at cohort level, across groups, not for a single person. Transposing a population average to an individual is a very widespread interpretive error in prevention marketing. Physical activity, alcohol, sleep or thyroid status can shift these estimates by several years, with no predictable direction. An announced biological age fifteen years above chronological age can trigger lasting anxiety. That anxiety continues when the result is repeated, because each confirmed measurement reinforces a mistaken reading of health status. The measure describes an algorithm index, not a laboratory examination.
On the clinical research side, panels of circulating proteins are tested on independent cohorts then validated for predicting symptoms and events. This work has not yet produced a decision tool accessible in routine practice. The rational course is to acknowledge the request, explain what the measurement does and does not do, then propose classic follow-up. Grip strength, walking speed and functional balance complete this picture by describing function and autonomy. These parameters are measured in the office, repeated at six months and make follow-up legible. They offer a direct marker of what the support is trying to improve.

Useful markers: comparative remeasurement is what gives follow-up its value
The value of a panel lies as much in the regularity of measurements as in their number. HbA1c is checked every three to six months with prediabetes, and the lipid panel every six to twelve months when risk is moderate. Values must be obtained under comparable conditions: the same laboratory if possible, away from an infectious episode, and fasting for glucose and lipids. The same test requested in two laboratories can differ by a few percent with no clinical reason. That reproducibility is what gives follow-up its value.
Individual biological variance commonly lies between 5 and 10% for several tests. Two HbA1c measurements taken a month apart can differ with no change in health status at all. The reference interval printed on the report describes a population, not an individual value to reach. It serves to place a result within the normal range, not to set a personal goal. Only variations that cross a decision threshold deserve action, and follow-up documents that decision. The professional records on the report the reference year, the sampling conditions and the value retained as the comparison point. Reading a series of results side by side avoids comparing an isolated point with a population average.
Frequency and justification belong in the follow-up plan, not only in test reports. A simple table sets the useful rhythm and involves the person in monitoring their own health path. Automatic reminders, secure digital spaces and home measurement devices make this continuity simpler than before. That continuity protects the quality of prevention over time, including when the person changes practitioner or laboratory.
The professional classifies each value and sets a remeasurement date
The professional classifies each value into three categories, which structures most of the action plan. A normal value calls for no action, a borderline value justifies monitoring or a change in habits, an abnormal value is confirmed then leads to medical advice. This three-way split avoids presenting out-of-range results as an emergency. For example, an HbA1c at 6.1% leads to structured support and a remeasurement at three months, not to immediate treatment. A triglyceride at 1.70 g/L first invites a look for excess alcohol or high glucose. A slightly elevated creatinine in a muscular person is read with the estimated filtration rate, which may remain normal. The report then states the reference interval, the date and the associated course of action.
The vocabulary used in the report changes how the person interprets their results. Speaking of values to monitor rather than worrying results reduces anxiety. That wording then supports adherence to follow-up. Explaining the notion of normal biological variation prevents a minimal difference from being experienced as a punishment. It also defuses requests for ever broader panels, by showing the hierarchy of priorities.
The goals that follow from the panel are expressed as observable behaviors, therefore checkable at the next remeasurement. Synchronizing the calendar of tests with the calendar of habits prevents follow-up from being organized around results alone. The three-category summary appears in the file shared with the person being supported, with the next dates. Biological age measurements have no place there, for lack of a validated course of action.

Sources
- 1.US Preventive Services Task Force. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force recommendation statement. JAMA. 2022.
- 2.Belsky DW, et al. Eleven telomere, epigenetic clock, and biomarker-composite quantifications of biological aging: do they measure the same thing? Am J Epidemiol. 2018.
- 3.Selvin E, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med. 2010.
- 4.Moqri M, et al. Biomarkers of aging for the identification and evaluation of longevity interventions. Cell. 2023.
- 5.Moqri M, et al. Validation of biomarkers of aging. Nat Med. 2024.
- 6.Aging Biomarker Consortium. Biomarkers of aging. Sci China Life Sci. 2023.
- 7.Behr LC, et al. 60 years of healthy aging: on definitions, biomarkers, scores and challenges. Ageing Res Rev. 2023.
Reading studies is one thing, turning them into a plan is another
The Longevity Practitioner certification teaches the method that turns this kind of data into an accompaniment decision: assess, prioritise, plan over 90 days, re-measure, and know when to hand over.
11 modules, €2,200. Enrol
Continue reading
Benjamin Sant
Co-founder of the School of Longevity
Cofounder of the School of Longevity with Tristan Maruyama. A former officer trained at Saint-Cyr from 2019 to 2022 and a coach since 2018, he has supported more than 4,000 people. He leads the School's editorial content with one constant principle: pass on only what can be situated, verified and applied seriously.
This article is published for information and education. It does not replace medical advice. For any personal health question, consult a healthcare professional.
